

CLAIMS

1. Use of a chemokine receptor antagonist in combination with a cyclosporin to produce a pharmaceutical composition for treating or preventing the rejection of transplanted organs, tissues or cells.
2. The use according to claim 1, wherein the chemokine receptor antagonist and the cyclosporin are used simultaneously, separately or sequentially.
3. The use according to any preceding claim, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.
4. The use according to claims 1 or 2, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.
5. The use according to claims 1 or 2, wherein the chemokine receptor antagonist is Met-RANTES.
6. The use according to any preceding claim, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.
7. The use according to any preceding claim, wherein the cyclosporin is cyclosporin A.
8. The use according to any preceding claim, for treating or preventing renal allograft transplantation.
9. Pharmaceutical composition containing a chemokine receptor antagonist and a cyclosporin, in the presence of one or more pharmaceutically acceptable excipients, for treating or preventing the rejection of transplanted organs, tissues or cells.

10. Pharmaceutical composition containing a chemokine receptor antagonist and a cyclosporin, in the presence of one or more pharmaceutically acceptable excipients, for the simultaneous, separate or sequential use of its active ingredients in treating or preventing the rejection of transplanted organs, tissues or cells.

5

11. The pharmaceutical composition according to claim 9 or 10, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

10

12. The pharmaceutical composition according to claims 9 or 10, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

13. The pharmaceutical composition according to claims 9 or 10, wherein the chemokine receptor antagonist is Met-RANTES.

15

14. The pharmaceutical composition according to any of claims 9 to 13, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

20

15. The pharmaceutical composition according to any of claims 10 to 14, wherein the cyclosporin is cyclosporin A.

16. The pharmaceutical composition according to any of claims 9 to 15, for treating or preventing renal allograft transplantation.

Add B1